- Home
- ONC vs CCI Comparison
ONC vs CCI Comparison
Compare ONC & CCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONC | CCI |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 39.4B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | ONC | CCI |
|---|---|---|
| Price | $276.64 | $82.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $377.91 | $106.67 |
| AVG Volume (30 Days) | 242.5K | ★ 2.4M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.00% |
| EPS Growth | N/A | ★ 111.25 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $4,264,000,000.00 |
| Revenue This Year | $759.19 | N/A |
| Revenue Next Year | $14.51 | $1.63 |
| P/E Ratio | $614.06 | ★ $84.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $196.53 | $77.89 |
| 52 Week High | $385.22 | $115.76 |
Technical Indicators
Market Signals| Indicator | ONC | CCI |
|---|---|---|
| Relative Strength Index (RSI) | 28.89 | 36.89 |
| Support Level | $239.25 | $77.89 |
| Resistance Level | $284.51 | $92.03 |
| Average True Range (ATR) | 7.11 | 1.97 |
| MACD | -2.02 | -0.68 |
| Stochastic Oscillator | 1.35 | 9.99 |
Price Performance
Historical ComparisonAbout ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
About CCI Crown Castle Inc.
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.